| IPR2022-01226 | Mylan Pharmaceuticals Inc. et al. v. Regeneron Pharmaceuticals, Inc. | Jul 1, 2022 |
| 1:22-cv-00061 | Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. | Aug 2, 2022 |
| IPR2023-00566 | Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. | Feb 10, 2023 |
| IPR2023-00533 | Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc. | Feb 10, 2023 |
| IPR2023-00739 | Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. | Mar 26, 2023 |
| 1:23-cv-00089 | Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc. | Nov 8, 2023 |
| IPR2024-00201 | Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc. | Nov 20, 2023 |
| 1:23-cv-00094 | Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD., | Nov 21, 2023 |
| 1:23-cv-00097 | Regeneron Pharmaceuticals, Inc. v. Formycon AG | Nov 29, 2023 |
| 2:24-cv-00264 | Regeneron Pharmaceuticals, Inc. v. Amgen, Inc. | Jan 10, 2024 |
| 1:24-md-03103 | In Re: Aflibercept Patent Litigation | Apr 11, 2024 |
| 1:24-cv-00039 | Regeneron Pharmaceuticals, Inc. v. Amgen, Inc. | Apr 16, 2024 |
| 1:24-cv-00053 | Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc. | May 17, 2024 |
| 3:24-cv-08760 | Regeneron Pharmaceuticals, Inc. v. SANDOZ INC. | Aug 26, 2024 |
| IPR2025-00176 | Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. | Nov 20, 2024 |
| IPR2025-00233 | Formycon AG v. Regeneron Pharmaceuticals, Inc. | Dec 2, 2024 |
| IPR2025-00456 | Celltrion, Inc. v. Regeneron Pharmaceuticals, Inc. | Jan 15, 2025 |
| IPR2025-01268 | Fresenius Kabi SwissBioSim GmbH et al. v. Regeneron Pharmaceuticals, Inc. | Jul 14, 2025 |
